Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of$ 0.83. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.30%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of$ 0.98 per share when it actually produced a loss of $0.71, delivering a surprise ...